Novel immunotherapy strategies for hepatobiliary cancers

Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous on...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-09, Vol.10 (12), p.1077-1091
Main Authors: DeLeon, Thomas T, Zhou, Yumei, Nagalo, Bolni M, Yokoda, Raquel T, Ahn, Daniel H, Ramanathan, Ramesh K, Salomao, Marcela A, Aqel, Bashar A, Mahipal, Amit, Bekaii-Saab, Tanios S, Borad, Mitesh J
Format: Article
Language:English
Subjects:
Antigens
biliary tract cancers
Biomarkers
Cancer therapies
CAR-T-cell therapy
Chimeric antigen receptors
Cholangiocarcinoma
Clinical trials
CTLA-4 protein
Epidermal growth factor
FDA approval
Gallbladder
Hepatitis
hepatocellular carcinoma
Immune checkpoint
Immunotherapy
Leukemia
Ligands
Liver cancer
Lymphocytes
Lymphocytes T
Medical prognosis
Metastasis
Oncolysis
oncolytic virotherapy
Patients
PD-1 protein
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2018-0024